Driving CAR T cells towards dermatologic oncology

Whereas approximately half of metastatic melanoma patients benefit from combined immune checkpoint inhibition targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed cell death 1 (PD-1), for those who do not respond, further strategies treatment options need to be developed. Thus, focus is turning the use chimeric antigen receptor (CAR) T cells, a novel therapy that has yet achieved major breakthrough in solid tumors despite impressive response rates reported their hematologic malignancies. In other tumor entities, different problems still addressed improve this therapy, with mechanisms counteract escape being one them. context, we could show feasibility combining two transfection methods – lentiviral transduction RNA-electroporation equipping same lymphocyte antigen-specific receptors. While analysis required transfer strategy bench bedside, appropriate target antigens avoid on-target/off-tumor toxicities additional optimization increase CAR power are also needed maximize potential dermatologic oncology.